New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials

医学 腺癌 肺癌 病理 肺科医生 癌症 外科病理学 肿瘤科 内科学 重症监护医学
作者
William D. Travis,Élisabeth Brambilla,Gregory J. Riely
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:31 (8): 992-1001 被引量:596
标识
DOI:10.1200/jco.2012.46.9270
摘要

We summarize significant changes in pathologic classification of lung cancer resulting from the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) lung adenocarcinoma classification. The classification was developed by an international core panel of experts representing IASLC, ATS, and ERS with oncologists/pulmonologists, pathologists, radiologists, molecular biologists, and thoracic surgeons. Because 70% of patients with lung cancer present with advanced stages, a new approach to small biopsies and cytology with specific terminology and criteria focused on the need for distinguishing squamous cell carcinoma from adenocarcinoma and on molecular testing for EGFR mutations and ALK rearrangement. Tumors previously classified as non-small-cell carcinoma, not otherwise specified, because of the lack of clear squamous or adenocarcinoma morphology should be classified further by using a limited immunohistochemical workup to preserve tissue for molecular testing. The terms "bronchioloalveolar carcinoma" and "mixed subtype adenocarcinoma" have been discontinued. For resected adenocarcinomas, new concepts of adenocarcinoma in situ and minimally invasive adenocarcinoma define patients who, if they undergo complete resection, will have 100% disease-free survival. Invasive adenocarcinomas are now classified by predominant pattern after using comprehensive histologic subtyping with lepidic, acinar, papillary, and solid patterns; micropapillary is added as a new histologic subtype with poor prognosis. Former mucinous bronchioloalveolar carcinomas are now called "invasive mucinous adenocarcinoma." Because the lung cancer field is now rapidly evolving with new advances occurring on a frequent basis, particularly in the molecular arena, this classification provides a much needed standard for pathologic diagnosis not only for patient care but also for clinical trials and TNM classification.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
舒舒发布了新的文献求助10
刚刚
fanjizji完成签到 ,获得积分10
1秒前
1秒前
1秒前
syvshc的应助被CC采纳,获得10
1秒前
detail完成签到 ,获得积分10
1秒前
1秒前
可靠的南露完成签到,获得积分10
3秒前
dzhang198777发布了新的文献求助10
3秒前
我爱读文献完成签到,获得积分10
3秒前
胡图图关注了科研通微信公众号
3秒前
3秒前
mask完成签到 ,获得积分10
4秒前
4秒前
ashleyjr完成签到,获得积分10
4秒前
栗子熊完成签到,获得积分10
4秒前
酷仔仔发布了新的文献求助30
4秒前
九耳久知完成签到,获得积分10
4秒前
快乐tomato举报求助违规成功
4秒前
不爱看文献头疼举报求助违规成功
4秒前
Jun举报求助违规成功
4秒前
4秒前
5秒前
秋风的应助被yjw0526采纳,获得10
5秒前
wzh发布了新的文献求助10
5秒前
华仔的应助被NN采纳,获得30
6秒前
GPTea的应助被EKKO采纳,获得20
6秒前
6秒前
Aero发布了新的文献求助20
6秒前
7秒前
Efrain关注了科研通微信公众号
7秒前
布偶修喵完成签到,获得积分10
7秒前
大个的应助被Jake采纳,获得10
7秒前
7秒前
超级的芷荷完成签到,获得积分20
8秒前
CarryLJR的应助被踏实的代曼采纳,获得10
8秒前
今后的应助被危机的水之采纳,获得30
9秒前
9秒前
尿尿king发布了新的文献求助10
9秒前
67完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451